Physician profile
Jonathan Benjamin Kahn
NPI 1457508731
$3,325.52
in general payments reported to CMS, 2019-2025
20 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $437 · 2021: $564 · 2022: $373 · 2023: $552 · 2024: $278 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $829.67 | 2019-2025 | Clareon Panoptix Pro, Clareon, Acrysof Iq Panoptix Uv Iol |
| Sun Pharmaceutical Industries INC. | $781.64 | 2019-2023 | Cequa |
| Allergan, INC. | $234.02 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $210.79 | 2019-2023 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $179.57 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Carl Zeiss Meditec Cataract Technology INC. | $167.08 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $143.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $140.87 | 2020-2023 | Acthar |
| Abbvie INC. | $127.60 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Amgen INC. | $122.43 | 2024 | Uplizna |
| Kala Pharmaceuticals, INC. | $49.45 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $45.27 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $40.15 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $40.02 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $25.59 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.15 | 2021 | |
| Sight Sciences, INC. | $18.77 | 2023 | Tearcare System |
| Biotissue Holdings INC. | $18.39 | 2021 | |
| Optos, INC. | $4.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.